These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 36703243)

  • 1. Cardiovascular Toxicity of Androgen Deprivation Therapy.
    Boland J; Choi W; Lee M; Lin J
    Curr Cardiol Rep; 2021 Jul; 23(8):109. PubMed ID: 34216282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
    Lowentritt B; Fallick M; Pruett J; Jiang T; Li E; Brown B; Dufour R
    Urol Pract; 2024 Jan; 11(1):154-161. PubMed ID: 37914225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.
    Zhao J; Zhu S; Sun L; Meng F; Zhao L; Zhao Y; Tian H; Li P; Niu Y
    PLoS One; 2014; 9(9):e107516. PubMed ID: 25264674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
    Merseburger AS; Bakshi G; Chen DY; Chiong E; Jabbour M; Joung JY; Lai AY; Lawrentschuk N; Le TA; Ng CF; Ng CT; Ong TA; Pang JS; Rabah DM; Ragavan N; Sase K; Suzuki H; Teo MMH; Uemura H; Woo HH
    World J Urol; 2024 Mar; 42(1):156. PubMed ID: 38483562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil.
    Xi L; Kraskauskas D; Muniyan S; Batra SK; Kukreja RC
    Am J Physiol Regul Integr Comp Physiol; 2023 Apr; 324(4):R589-R600. PubMed ID: 36878484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
    Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T
    Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study.
    Chan JSK; Satti DI; Lee YHA; Hui JMH; Dee EC; Ng K; Liu K; Tse G; Ng CF
    Br J Cancer; 2023 Jun; 128(12):2253-2260. PubMed ID: 37076564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LHRH Agonists for the Treatment of Prostate Cancer: 2012.
    Lepor H; Shore ND
    Rev Urol; 2012; 14(1-2):1-12. PubMed ID: 23172994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.
    Lebret T; Ruffion A; Latorzeff I; Zerbib M; Moreau JL; Rossi D; Pello-Leprince-Ringuet N; Perrot V; Hennequin C
    Ther Adv Urol; 2018 Dec; 10(12):365-376. PubMed ID: 30574196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Natural and Synthetic Compounds in Modulating NRF2/KEAP1 Signaling Pathway in Prostate Cancer.
    Tossetta G; Fantone S; Marzioni D; Mazzucchelli R
    Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
    MacLennan S; Azevedo N; Duncan E; Dunsmore J; Fullwood L; Lumen N; Plass K; Ribal MJ; Roobol MJ; Nieboer D; Schouten N; Skolarus TA; Smith EJ; N'Dow J; Mottet N; Briganti A;
    Eur Urol; 2023 May; 83(5):393-401. PubMed ID: 36639296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.
    Morgia G; Russo GI; Tubaro A; Bortolus R; Randone D; Gabriele P; Trippa F; Zattoni F; Porena M; Mirone V; Serni S; Del Nero A; Lay G; Ricardi U; Rocco F; Terrone C; Pagliarulo A; Ludovico G; Vespasiani G; Brausi M; Simeone C; Novella G; Carmignani G; Leonardi R; Pinnarò P; De Paula U; Corvò R; Tenaglia R; Siracusano S; Mantini G; Gontero P; Savoca G; Ficarra V;
    BJU Int; 2016 Jun; 117(6):867-73. PubMed ID: 26332130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriateness and complications of androgen deprivation therapy for prostate cancer: Can we do better? A retrospective observational analysis from a referral center.
    Oderda M; Bertetto O; Barbera G; Calleris G; Falcone M; Filippini C; Marquis A; Marra G; Montefusco G; Peretti F; Gontero P
    Urologia; 2023 Feb; 90(1):100-108. PubMed ID: 36703243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.